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Background: Periodic monitoring of antimicrobial resistance trends of clinically important 
anaerobic bacteria such as Bacteroides fragilis group organisms is required. We deter-
mined the antimicrobial susceptibilities of clinical isolates of B. fragilis group organisms 
recovered from 2009 to 2012 in a tertiary-care hospital in Korea.
Methods: A total of 180 nonduplicate clinical isolates of B. fragilis group organisms were 
collected in a tertiary care hospital. The species were identified by conventional methods: 
the ATB 32A rapid identification system (bioMérieux, France) and the Vitek MS matrix-as-
sisted laser desorption/ionization time-of-flight mass spectrometry (bioMérieux). Antimi-
crobial susceptibility was determined by the CLSI agar dilution method.
Results: Imipenem and meropenem resistance rates were 0-6% for B. fragilis group iso-
lates. The rate of resistance to piperacillin-tazobactam was 2% for B. fragilis and 0% for 
other Bacteroides species, but 17% for B. thetaiotaomicron isolates. High resistance rates 
to piperacillin (72% and 69%), cefotetan (89% and 58%), and clindamycin (83% and 
69%) were observed for B. thetaiotaomicron and other Bacteroides spp. The moxifloxacin 
resistance rate was 27% for other Bacteroides spp. The MIC50 and MIC90 of tigecycline 
were 2-4 μg/mL and 8-16 μg/mL, respectively. No isolates were resistant to chlorampheni-
col or metronidazole.
Conclusions: Imipenem, meropenem, chloramphenicol, and metronidazole remain active 
against B. fragilis group isolates. Moxifloxacin and tigecycline resistance rates are 2-27% 
and 8-15% for B. fragilis group isolates, respectively. 
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INTRODUCTION
Bacteroides fragilis group organisms are important anaerobic 
pathogens that frequently cause various infections such as in-
tra-abdominal infection, postoperative wound infection, and 
bacteremia in humans [1-4]. These organisms are the most an-
tibiotic-resistant among the anaerobic isolates and are responsi-
ble for high rates of morbidity and mortality [4-6].
 According to the CLSI guidelines, routine susceptibility testing 
may not be necessary for many individual patient isolates [7-9], 
because predicting and testing the susceptibility of anaerobes is 
technically difficult and time-consuming. However, antimicrobial 
resistance of B. fragilis group organisms varies by geographic 
location and species [1, 2, 5, 7, 10]. Furthermore, antimicrobial 
resistance of these organisms has consistently increased over 
the past few decades, and their susceptibility to antimicrobial 
Yim JS, et al.
Antimicrobial susceptibility of B. fragilis group 
http://dx.doi.org/10.3343/alm.2015.35.1.94 www.annlabmed.org  95
agents has become less predictable. Therefore, periodic and lo-
cal surveillance studies are considered necessary, and current 
susceptibility data are important for empirical antimicrobial ther-
apy.
 Most susceptibility studies use the CLSI methodology. How-
ever, the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) publishes its own breakpoints, not all of which 
are equivalent to those of the CLSI [11]. Therefore, resistance 
rates may differ depending on the breakpoint used.
 In this study, we determined the current susceptibilities of 
clinical isolates of the B. fragilis group organisms recovered in a 
tertiary-care hospital in Korea from 2009 to 2012, and we com-
pared the resistant rates using both the CLSI and EUCAST 
breakpoints. 
METHODS
1. Bacterial isolates 
B. fragilis group organisms were isolated from blood, normally 
sterile body fluid, and abscess specimens in a university hospi-
tal in Korea between 2009 and 2012. All isolates were identified 
by conventional methods, a commercial rapid identification kit 
(ATB 32A, ANC; bioMérieux, Marcy I’Etoile, France) and matrix-
assisted laser desorption/ionization time-of-flight mass spec-
trometry (MALDI-TOF MS; Vitek MS, bioMérieux). A total of 180 
nonduplicate isolates were used in this study, including 86 B. 
fragilis, 46 B. thetaiotaomicron, 20 Bacteroides vulgatus, 13 Bac-
teroides ovatus, 13 Parabacteroides distasonis and 2 Bacteroi-
des uniformis isolates. 
2. Antimicrobial susceptibility testing
Antimicrobial susceptibility was determined by the CLSI agar di-
lution method [9]. The medium used was Brucella agar (Becton 
Dickinson, Cockeysville, MD, USA) supplemented with 5 μg/mL 
hemin, 1 μg/mL vitamin K1, and 5% laked sheep blood. The an-
timicrobials used were piperacillin and tazobactam (Yuhan, 
Seoul, Korea), cefoxitin (Merck Sharp & Dohme, West Point, 
PA, USA), cefotetan (Daiichi Pharmaceutical, Tokyo, Japan), 
clindamycin (Korea Upjohn, Seoul, Korea), imipenem and met-
ronidazole (ChoongWae, Seoul, Korea), chloramphenicol (Chong 
Kun Dang, Seoul, Korea), meropenem (Sumitomo, Tokyo, Ja-
pan), moxifloxacin (Bayer Korea, Seoul, Korea) and tigecycline 
(Wyeth Research, Pearl River, NY, USA); they were used in the 
powder form.
 For piperacillin-tazobactam, serial two-fold dilutions of piper-
acillin were combined with tazobactam at constant concentra-
tions of 4 μg/mL.
 The plates were inoculated with 105 colony-forming unit (CFU) 
with a Steers replicator (Craft Machine Inc., Woodline, PA, USA) 
and incubated in an anaerobic chamber (Forma Scientific, Mar-
ietta, OH, USA) for 48 hr at 37°C. The minimum inhibitory con-
centration (MIC) was defined as the lowest antibiotic concentra-
tion that caused a marked reduction in growth, such as from 
confluent growth to a haze, less than 10 tiny colonies, or several 
normal-sized colonies [9]. B. fragilis ATCC 25285 and B. the-
taiotaomicron ATCC 29741 were used as controls. The MICs 
were interpreted using the breakpoints recommended by CLSI 
and EUCAST for anaerobic bacteria [9, 13]. Since neither CLSI 
nor EUCAST recommends breakpoints for tigecycline, the 
breakpoints recommended by the US Food and Drug Adminis-
tration (FDA), ≤4 and ≥16 μg/mL, were used [12].
RESULTS
MIC ranges, MIC50s, MIC90s, and the percentages of resistant 
isolates for various antimicrobial agents are shown in Table 1.
Imipenem resistance rates were less than 5% for B. fragilis group 
isolates. There were four imipenem-resistant isolates: one B. 
fragilis, two B. thetaiotaomicron, and one B. ovatus. The resis-
tance rates to meropenem were 0-6% for all tested B. fragilis 
group organisms. High resistance rates to piperacillin were ob-
served (72% and 69%) for B. thetaiotaomicron isolates and other 
Bacteroides spp., respectively. The rate of resistance to piper-
acillin-tazobactam was 2% for B. fragilis, 0% for other Bacteroi-
des spp., and 17% for B. thetaiotaomicron isolates. Cefoxitin is 
an active β-lactam drug used against B. fragilis group organ-
isms, but our results showed an increase in resistance rates to 
this drug. The rates of resistance to cefotetan (89% and 58%) 
increased prominently for B. thetaiotaomicron isolates and other 
Bacteroides spp., respectively. The resistance rates for clindamy-
cin were 83% and 69% for B. thetaiotaomicron and other Bac-
teroides spp., respectively. The resistance rates for moxifloxacin 
were 8%, 2%, and 27% for B. fragilis, B. thetaiotaomicron, and 
other Bacteroides spp., respectively. The MIC range for tigecy-
cline was ≤0.06-32 μg/mL for all B. fragilis group isolates. The 
resistance rates of tigecycline were 15%, 13%, and 8% for B. fra-
gilis, B. thetaiotaomicron, and other Bacteroides spp., respec-
tively. 
 All the isolates were inhibited by ≤8 μg/mL chloramphenicol 
or metronidazole, to which no isolates were resistant.
 The EUCAST breakpoints were equal to or lower than the 
CLSI breakpoints for most antibiotics tested in this study. Large 
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Table 1. Antimicrobial activity against 180 Bacteroides fragilis group organisms isolated from 2009 to 2012 in a Korean tertiary care univer-
sity hospital
Organism (N of isolates) and 
antimicrobial agent
MIC (μg/mL)
CLSI (μg/mL) EUCAST (μg/mL)
Susceptibility Susceptibility (%) Breakpoints Susceptibility (%)
Range MIC50 MIC90 S R S R S R S R
Bacteroides fragilis (86)
   Piperacillin 2->256 8 >256 ≤32 ≥128 69 24 ≤16 >16 67 33
   Piperacillin-tazobactam ≤0.06->128 0.5 2 ≤32 ≥128 98 2 ≤8 >16 98 2
   Cefoxitin 4-128 8 32 ≤16 ≥64 88 3 -† - - -
   Cefotetan 2->128 8 64 ≤16 ≥64 84 13 - - - -
   Imipenem 0.06->128 0.12 1 ≤4 ≥16 99 1 ≤2 >8 97 1
   Meropenem 0.12->128 0.25 4 ≤4 ≥16 91 6 ≤2 >8 86 6
   Clindamycin ≤0.06->128 1 >128 ≤2 ≥8 60 35 ≤4 >4 65 35
   Moxifloxacin 0.25-32 0.5 2 ≤2 ≥8 91 8 - - - -
   Chloramphenicol 4-8 4 8 ≤8 ≥32 100 0 ≤8 >8 100 0
   Metronidazole 0.5-4 2 4 ≤8 ≥32 100 0 ≤4 >4 100 0
   Tigecycline* 0.5-32 2 16 ≤4 ≥16 67 15 ≤4  ≥16 67 15
Bacteroides thetaiotaomicron (46)
   Piperacillin 16->256 >256 >256  ≤32 ≥128 24 72 ≤16 >16 2 98
   Piperacillin-tazobactam 4->128 16 >128  ≤32 ≥128 83 17 ≤8 >16 24 41
   Cefoxitin 16->128 32 64  ≤16 ≥64 24 15 - - - -
   Cefotetan 32->128 64 >128  ≤16 ≥64 0 89 - - - -
   Imipenem 0.12-32 0.5 8  ≤4 ≥16 87 4 ≤2 >8 83 4
   Meropenem 0.25-4 0.5 2  ≤4 ≥16 100 0 ≤2 >8 91 0
   Clindamycin 4->128 >128 >128  ≤2 ≥8 0 83 ≤4 >4 17 83
   Moxifloxacin 0.5-32 2 4  ≤2 ≥8 87 2 - - - -
   Chloramphenicol 4-8 8 8  ≤8 ≥32 100 0 ≤8 >8 100 0
   Metronidazole 0.5-4 2 4  ≤8 ≥32 100 0 ≤4 >4 100 0
   Tigecycline 0.5-16 4 16  ≤4 ≥16 67 13 ≤4 ≥16 67 13
Other Bacteroides species (48) 
   Piperacillin ≤1->256 >256 >256 ≤32 ≥128 31 69 ≤16 >16 31 69
   Piperacillin-tazobactam ≤0.06-64 4 32 ≤32 ≥128 98 0 ≤8 >16 81 13
   Cefoxitin ≤1->128 16 64 ≤16 ≥64 67 15 - - - -
   Cefotetan 2->128 64 >128 ≤16 ≥64 27 58 - - - -
   Imipenem 0.06-32 0.5 2 ≤4 ≥16 98 2 ≤2 >8 98 2
   Meropenem 0.03-64 0.5 2 ≤4 ≥16 94 2 ≤2 >8 92 2
   Clindamycin ≤0.06->128 >128 128 ≤2 ≥8 31 69 ≤4 >4 31 69
   Moxifloxacin ≤0.06-128 1 32 ≤2 ≥8 69 27 - - - -
   Chloramphenicol 1-8 4 8 ≤8 ≥32 100 0 ≤8 >8 100 0
   Metronidazole ≤0.12-4 2 2 ≤8 ≥32 100 0 ≤4 >4 100 0
   Tigecycline ≤0.06-16 4 8 ≤4 ≥16 67 8 ≤4  ≥16 67 8
*No CLSI or EUCAST breakpoints available; FDA breakpoints were used. †No EUCAST breadpoints available.
Abbreviations: MIC, minimum inhibitory concentration; EUCAST, European Committee on Antimicrobial Susceptibility Testing; S, susceptible; R, resistant.
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differences in resistance rates when analyzed with CLSI or EU-
CAST breakpoints were observed for piperacillin: 24% vs. 33% 
for B. fragilis and 72% vs. 98% for B. thetaiotaomicron, respec-
tively. The piperacillin-tazobactam resistance rates were 17% 
vs. 41% for B. thetaiotaomicron and 0% vs. 13% for other Bac-
teroides species by CLSI or EUCAST breakpoints, respectively. 
No other resistance rates differed by CLSI or EUCAST.
DISCUSSION
Susceptibility testing had not been routinely used for treating in-
fections involving anaerobes because of the availability of broad-
spectrum antibiotics, delayed reporting due to slow growth of 
bacteria, and the assumption that anaerobe susceptibility patterns 
do not change [13, 14]. However, antimicrobial susceptibility test-
ing is indispensable in patients with serious or life-threatening in-
fections, because the clinical outcome correlates with the test re-
sults [14, 15]. In addition, an increasing resistance of anaerobes 
to several antibiotics has recently been reported [3, 7, 11].
 Carbapenems are usually highly active against B. fragilis 
group isolates. A study performed from 1989 to 1990 found no 
carbapenem-resistant B. fragilis group isolates [16]. Although 
the level of carbapenem resistance has not changed markedly 
during the past 25 yr, the percentage of isolates with reduced 
susceptibilities has steadily increased. In this study, the merope-
nem resistance rate was 6% for B. fragilis isolates. This rate is 
higher than the approximately 1% rate reported for B. fragilis in 
Europe, USA, and Canada, but lower than the rate (7.5%) re-
ported in Germany by Seifert et al. [10]. Piperacillin resistance 
increased to 72% and 69% for B. thetaiotaomicron and other 
Bacteroides group spp., respectively, which are higher than the 
rates reported 10 yr ago (42% and 49%, respectively). A study 
performed from 1997 to 2004 reported the MIC90 and resis-
tance rate to piperacillin-tazobactam to be 16 μg/mL and 4% 
[6]; in this study, they were found to increase to >128 μg/mL 
and 17%, respectively, for B. thetaiotaomicron. These rates 
were slightly higher than that reported for piperacillin-tazobac-
tam in a multicenter survey of 13 European countries; the re-
ported MIC90 was 128 μg/mL and the resistance rate was 12% 
[3]. Other countries, such as the USA, Canada, and Argentina, 
have reported relatively low piperacillin-tazobactam resistance 
rates (<4%) for all B. fragilis group isolates [2, 7, 14]. Compared 
to cefoxitin, cefotetan is less effective against B. fragilis group 
isolates. Recently, the Infectious Diseases Society of America 
(IDSA) removed cefotetan from its list of recommended thera-
pies for intra-abdominal infections because it has poor activity 
against the B. fragilis group and results in clinical failures [11]. 
The present study also reported a poor activity of cefotetan; the 
resistance rates were 89% for B. thetaiotaomicron and 58% for 
other B. fragilis group organisms.
 Moxifloxacin had good in vitro activity against most anaerobic 
bacteria when first introduced [15]; however, various recent sur-
veys have reported increased resistance among Bacteroides 
spp. [2, 3, 10, 14, 16, 17]. Our previous studies also reported 
increased resistance to moxifloxacin among Bacteroides spe-
cies and found a resistance rate of 11-20% in B. fragilis [8, 17]. 
However, the present data for moxifloxacin show low resistance 
(8% and 2%, respectively) for B. fragilis and B. thetaiotaomi-
cron and a relatively high resistance rate (27%) in other Bacte-
roides species (Table 1). 
 Tigecycline has been approved by the FDA for use in compli-
cated skin and soft tissue infections and intra-abdominal infec-
tions. Despite expectations, tigecycline resistance rates were 
8-15% for B. fragilis group species in this study. Some studies 
have shown variable resistance rates, such as 0-10% in Europe 
and Argentina [3, 7] and 0-17.5% in Canada [2]. In addition, 
this study found a relatively high percentage of intermediate 
rates (17-25% for all B. fragilis group isolates); therefore, con-
tinuous attention is required.
 Metronidazole and chloramphenicol resistance in B. fragilis 
group isolates have recently been reported worldwide [3, 10, 
15, 18, 19]. Resistance to metronidazole was recently reported 
to be <1% in Europe and the USA [3, 14], but it has been ap-
proaching 1% in many European countries [10]. However, no B. 
fragilis group isolates that are resistant to these agents have 
been reported previously in Korea. Consistent with previous re-
ports [6, 8, 17, 20], susceptibility patterns for metronidazole 
and chloramphenicol remained stable. 
 To compare the differences between using CLSI and EUCAST 
clinical breakpoints, the available EUCAST breakpoints were 
also used. EUCAST breakpoints were not available for cefoxitin, 
cefotetan, moxifloxacin, and tigecycline. EUCAST stated that 
there is insufficient evidence that anaerobes are a good target 
for therapy with moxifloxacin [13]. They also stated that there is 
clinical evidence of tigecycline activity in mixed intra-abdominal 
infections, but no correlation between MIC values and clinical 
outcomes; therefore, no breakpoints were given [13]. The most 
prominent difference between CLSI and EUCAST is the higher 
CLSI breakpoint for piperacillin and piperacillin-tazobactam. We 
expected higher resistance rates according to the EUCAST 
breakpoints; however, only the piperacillin and piperacillin-tazo-
bactam resistance patterns differed significantly. 
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 In conclusion, imipenem, meropenem, chloramphenicol, and 
metronidazole remain active against B. fragilis group isolates. 
Moxifloxacin resistance rates were 8%, 2%, and 27% for B. fra-
gilis, B. thetaiotaomicron, and other Bacteroides spp., respec-
tively. Tigecycline resistance rates for B. fragilis group species 
were 8-15%. Therefore, periodic monitoring is needed to dem-
onstrate changes in the antimicrobial susceptibility patterns of B. 
fragilis group isolates. 
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